Eisai Forms Alliance With Swedish Firm for Alzheimer Drug Research
Posted on: Monday, 29 August 2005, 15:00 CDT
Aug. 26--TOKYO -- Major drug maker Eisai Co. said Friday it has formed a strategic alliance with a Swedish bio venture to develop immunotherapy for Alzheimer's disease.
The deal will give Eisai the preferential right to use BioArctic Neuroscience Inc.'s research results on Alzheimer's disease, the Tokyo-based firm said.
Eisai has been actively forming alliances with outside entities to expand its product line-up in the neurology area.
Eisai says sales of Aricept, which is used to treat Alzheimer's disease, grew by 15 percent in fiscal 2004 over the previous year.
-----
To see more of Kyodo News International, go to http://www.kyodonews.com
Copyright (c) 2005, Kyodo News International, Tokyo
Distributed by Knight Ridder/Tribune Business News.
For information on republishing this content, contact us at (800) 661-2511 (U.S.), (213) 237-4914 (worldwide), fax (213) 237-6515, or e-mail reprints@krtinfo.com.
ESALY, 4523,
Source: Kyodo News International, Tokyo
Related Articles
- Eisai Inc. And the Alzheimer's Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
- Umbilical Cord Cells May Help Alzheimer's
- International Brain Aging Expert Challenges the Existence of Alzheimer's As a 'Disease'
- Aricept May Help in Radiotherapy
- Scientists Make Discovery in Alzheimer's
- Toxin Found in Water With Blue-Green Algae
- Brain Toxin Found in Algae in Water; Possible Link to Alzheimer's, Other Ills Studied
- Predix Pharmaceuticals' Novel 5-HT4 Agonist for Alzheimer's Subject of Presentation at AD/PD 2005
- The Flames of Inflammation
- Alzheimer's, Other Diseases Often Mistaken
 |
 |
User Comments (0)
RSS Feeds